Medpace Holdings (MEDP) Stock Valuation Check After Mixed Recent Share Performance

Simply Wall St.06-16

AdvertisementMedpace Holdings overview after recent share performance Medpace Holdings (MEDP) has drawn fresh attention after a solid move in its share price over the past month, inviting investors to...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2643731854?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-06-16 14:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643731854","market":"hk","top_or_hot":-1,"title":"Medpace Holdings (MEDP) Stock Valuation Check After Mixed Recent Share Performance","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementMedpace Holdings overview after recent share performance Medpace Holdings (MEDP) has drawn fresh attention after a solid move in its share price over the past month, inviting investors to...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-medp/medpace-holdings/news/medpace-holdings-medp-stock-valuation-check-after-mixed-rece\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medpace Holdings (MEDP) Stock Valuation Check After Mixed Recent Share Performance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedpace Holdings (MEDP) Stock Valuation Check After Mixed Recent Share Performance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-16 14:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-medp/medpace-holdings/news/medpace-holdings-medp-stock-valuation-check-after-mixed-rece><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementMedpace Holdings overview after recent share performance Medpace Holdings (MEDP) has drawn fresh attention after a solid move in its share price over the past month, inviting investors to...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-medp/medpace-holdings/news/medpace-holdings-medp-stock-valuation-check-after-mixed-rece\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065170008.USD","symbol_name":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-medp/medpace-holdings/news/medpace-holdings-medp-stock-valuation-check-after-mixed-rece","article_id":"2643731854","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-medp/medpace-holdings/news/medpace-holdings-medp-stock-valuation-check-after-mixed-rece","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2643731854","pubTimestamp":1781591257,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Medpace Holdings overview after recent share performance\nMedpace Holdings (MEDP) has drawn fresh attention after a solid move in its share price over the past month, inviting investors to review how its current valuation lines up with recent fundamentals.\nSee our latest analysis for Medpace Holdings.\nThat recent 12.6% 1 month share price return stands out against a weaker year to date share price return, while a 1 year total shareholder return of 56.9% suggests longer term holders have still...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","BK4121":"生命科学工具和服务","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","BK4585":"ETF&股票定投概念","BK4588":"碎股","MEDP":"Medpace Holdings Inc."},"translate_title":"Medpace Holdings(MEDP)近期股价表现好坏参半后进行股票估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MEDP":1.5},"content_text":"AdvertisementMedpace Holdings overview after recent share performance Medpace Holdings (MEDP) has drawn fresh attention after a solid move in its share price over the past month, inviting investors to review how its current valuation lines up with recent fundamentals. See our latest analysis for Medpace Holdings. That recent 12.6% 1 month share price return stands out against a weaker year to date share price return, while a 1 year total shareholder return of 56.9% suggests longer term holders have still been rewarded. If you are comparing Medpace with other opportunities in healthcare, this could be a good moment to scan a wider set of clinical research and biotech players through 39 healthcare AI stocks. With Medpace trading around $467.50 and an intrinsic value estimate that sits lower, along with a mixed set of recent returns, investors may question whether the current price still leaves upside or if the market is already pricing in future growth. Most Popular Narrative: 6.5% Undervalued Against the last close of $467.50, the most followed narrative pegs Medpace's fair value near $500, suggesting the market price trails that estimate.  The rapid revenue acceleration in 2025 is heavily influenced by a therapeutic mix shift toward faster-burning studies (such as metabolic trials) with higher reimbursable costs, increasing \"pass-through\" revenue that is less margin-accretive, which could result in lower underlying revenue and EBITDA growth once this project mix normalizes.  Read the complete narrative. Read the complete narrative. Want to understand why a business built on clinical research could support a higher valuation? The narrative leans on steady earnings expansion, firm margins, and a future profit multiple that still sits below a key industry benchmark. Curious which specific growth and profitability assumptions have to hold for that fair value to stack up? Result: Fair Value of $500.08 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, it is worth considering that a declining backlog, along with higher staffing and trial costs, could pressure margins and limit how far this valuation narrative can extend.\nFind out about the key risks to this Medpace Holdings narrative. Next Steps If this mix of cautious and optimistic signals leaves you undecided, it is worth reviewing the underlying data, forward assumptions, and key rewards yourself. To see what has investors optimistic about Medpace, start with the 3 key rewards. Looking for more investment ideas? If Medpace has sharpened your focus, do not stop here. You can quickly widen your watchlist with other stocks that match different goals and risk levels.  Target fresh opportunities that the market may be overlooking by scanning a screener containing 20 high quality undiscovered gems tailored to strong fundamentals and quality financial profiles. Prioritize resilience by checking out 68 resilient stocks with low risk scores that pair lower risk scores with business models built for steadier performance. Strengthen your portfolio’s foundation by reviewing companies in the solid balance sheet and fundamentals stocks screener (48 results) and focusing on robust finances before sentiment shifts.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2643731854","isCrawlerRequest":true}